In primary lymph nodal staging of patients with high-risk and intermediate-risk prostate cancer, how critical is the role of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography?

被引:19
|
作者
Kulkarni, Smita Chinmay [1 ]
Sundaram, Palaniswamy Shanmuga [1 ]
Padma, Subramanyam [1 ]
机构
[1] Amrita Vishwavidyapeetham, Dept Nucl Med & Mol Imaging, Amrita Inst Med Sci, Kochi, Kerala, India
关键词
Gallium-68 prostate-specific membrane antigen; positron emission tomography-computed tomography; prostate neoplasm; prostate-specific antigen; magnetic resonance imaging; ACCURACY; NODES; MRI; CT;
D O I
10.1097/MNM.0000000000001110
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objective To assess the diagnostic performance of Gallium-68 prostate-specific membrane antigen positron emission tomography-computed tomography (Ga-68-PSMA PET-CT) in primary lymphnodal staging of patients with intermediate-risk and high-risk prostate cancer and to compare it with multiparametric MRI (mp-MRI) whenever available. Materials and methods Ga-68-PSMA PET-CT scans of 51 patients (average age 66.0 +/- 7.0 years) with biopsy-proven intermediate-risk and high-risk prostatic cancer who were managed by radical prostatectomy and extended pelvic lymph nodal dissection were retrospectively analyzed. Diagnostic performance of Ga-68-PSMA PET-CT in primary lymph nodal staging was analyzed using histopathology as reference. Diagnostic performance of mp-MRI, which was available in 35/51 patients was compared with that of Ga-68-PSMA PET-CT. Results Univariate analysis of patient characteristics showed significant influence of the pathological T-stage and maximum standard uptake value (SUV)max of the primary lesion on presence of nodal metastasis. In 51 patients, for patient-based analysis, the sensitivity, specificity and accuracy of Ga-68-PSMA PET-CT in detecting lymphnodal metastases were 80, 90.3 and 86.3%, respectively, and for lesion-based analysis 69.2, 99.6 and 98.4%, respectively. In 35/51 patients (who also had undergone mp-MRI), the patient-based and lesion-based sensitivity, specificity, and accuracy of Ga-68-PSMA PET-CT were 81.3, 84.2, 82.8% and 70.9, 99.5, 98.2%, respectively, and that of mp-MRI were 43.7, 78.9, 62.8% and 32.2, 98.5, 95.5%, respectively. For lesion-based analysis, Ga-68-PSMA PET-CT performed better than mp-MRI (P value = 0.04). Conclusion Ga-68-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment. It performed better than mp-MRI in a subset of patients.
引用
收藏
页码:139 / 146
页数:8
相关论文
共 50 条
  • [41] The role of prostate-specific membrane antigen PET/computed tomography in the management of prostate cancer patients: could we ask for more?
    Mei, Riccardo
    Farolfi, Andrea
    Morigi, Joshua James
    Fanti, Stefano
    CURRENT OPINION IN UROLOGY, 2022, 32 (03) : 269 - 276
  • [42] Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
    Woo, Sungmin
    Ghafoor, Soleen
    Becker, Anton S.
    Han, Sangwon
    Wibmer, Andreas G.
    Hricak, Hedvig
    Burger, Irene A.
    Schoder, Heiko
    Vargas, Hebert Alberto
    EUROPEAN JOURNAL OF HYBRID IMAGING, 2020, 4 (01):
  • [43] The Additive Diagnostic Value of Prostate-specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study
    Emmett, Louise
    Buteau, James
    Papa, Nathan
    Moon, Daniel
    Thompson, James
    Roberts, Matthew J.
    Rasiah, Kris
    Pattison, David A.
    Yaxley, John
    Thomas, Paul
    Hutton, Anthony C.
    Agrawal, Shikha
    Amin, Amer
    Blazevski, Alexandar
    Chalasani, Venu
    Ho, Bao
    Nguyen, Andrew
    Liu, Victor
    Lee, Jonathan
    Sheehan-Dare, Gemma
    Kooner, Raji
    Coughlin, Geoff
    Chan, Lyn
    Cusick, Thomas
    Namdarian, Benjamin
    Kapoor, Jada
    Alghazo, Omar
    Woo, Henry H.
    Lawrentschuk, Nathan
    Murphy, Declan
    Hofman, Michael S.
    Stricker, Phillip
    EUROPEAN UROLOGY, 2021, 80 (06) : 682 - 689
  • [44] Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node Metastases
    Budiharto, Tom
    Joniau, Steven
    Lerut, Evelyne
    Van den Bergh, Laura
    Mottaghy, Felix
    Deroose, Christophe M.
    Oyen, Raymond
    Ameye, Filip
    Bogaerts, Kris
    Haustermans, Karin
    Van Poppel, Hendrik
    EUROPEAN UROLOGY, 2011, 60 (01) : 125 - 130
  • [45] The Sensitivity and Specificity of Multiparametric Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Predicting Seminal Vesicle Invasion in Clinically Significant Prostate Cancer: A Multicenter Retrospective Study
    Sitharthan, Darshan
    Kang, Song
    Treacy, Patrick-Julien
    Bird, Jacob
    Alexander, Kate
    Karunaratne, Sascha
    Leslie, Scott
    Chan, Lewis
    Steffens, Daniel
    Thanigasalam, Ruban
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (15)
  • [46] Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis
    Sungmin Woo
    Soleen Ghafoor
    Anton S. Becker
    Sangwon Han
    Andreas G. Wibmer
    Hedvig Hricak
    Irene A. Burger
    Heiko Schöder
    Hebert Alberto Vargas
    European Journal of Hybrid Imaging, 4
  • [47] Clinical Usefulness of Prostate-specific Membrane Antigen-ligand Positron Emission Tomography/Computed Tomography for the Detection of Prostate Cancer Biochemical Recurrence after Primary Radiation Therapy in Patients with Prostate-specific Antigen Below the Phoenix Threshold: Systematic Review and Meta-analysis
    Subiela, J. D.
    Selles, E. Gomis
    Maldonado, A.
    Campos, F. Lopez
    Ovide, J. Aumatell
    Illarramendi, O. Ajuria
    Gonzalez-Padilla, D. A.
    Gajate, P.
    Polledo, L. E. Ortega
    Gregorio, S. Alonso y
    Guerrero-Ramos, F.
    Dos Santos, V. Gomez
    Rodriguez-Patron, R.
    Calais, J.
    Kishan, A. U.
    Revilla, F. J. Burgos
    Counago, F.
    CLINICAL ONCOLOGY, 2023, 35 (12) : E676 - E688
  • [48] Utility of Choline Positron Emission Tomography/Computed Tomography for Lymph Node Involvement Identification in Intermediate- to High-risk Prostate Cancer: A Systematic Literature Review and Meta-analysis
    Evangelista, Laura
    Guttilla, Andrea
    Zattoni, Fabio
    Muzzio, Pier Carlo
    Zattoni, Filiberto
    EUROPEAN UROLOGY, 2013, 63 (06) : 1040 - 1048
  • [49] 18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer
    Harley, Simon J. D.
    Hoffmann, Richard
    Bartholomeusz, Dylan
    Sutherland, Peter
    Chatterton, Barry
    Kitchener, Michael
    Takhar, Prab
    Tsopelas, Chris
    Fuller, Andrew
    Wells, Richard
    Singh-Rai, Raj
    Bolt, John
    PROSTATE INTERNATIONAL, 2018, 6 (02) : 50 - 54
  • [50] Diagnostic Performance of 68Ga-PSMA-11 Positron Emission Tomography/Computed Tomography to Monitor Treatment Response in Patients with Metastatic Prostate Cancer: The Concordance Between Biochemical Response and Prostate-specific Membrane Antigen Results
    Esen, Baris
    Seymen, Hulya
    Tarim, Kayhan
    Koseoglu, Ersin
    Bolukbasi, Yasemin
    Falay, Okan
    Selcukbiricik, Fatih
    Mandel, Nil Molinas
    Kordan, Yakup
    Demirkol, Mehmet Onur
    Tilki, Derya
    Esen, Tarik
    EUROPEAN UROLOGY FOCUS, 2023, 9 (05): : 832 - 837